Comparative Pharmacology
Head-to-head clinical analysis: COMPAZINE versus METOZOLV ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPAZINE versus METOZOLV ODT.
COMPAZINE vs METOZOLV ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Selective 5-HT3 receptor antagonist; blocks serotonin action at vagal nerve terminals and in the chemoreceptor trigger zone, inhibiting emetic reflex.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
2.5 mg to 5 mg orally once daily, as disintegrating tablet; may increase to 10 mg if needed
None Documented
None Documented
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
~1.5–2 hours in normal renal function; prolonged to 10–20 hours in severe renal impairment (CrCl <30 mL/min).
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Renal: ~70% as unchanged drug; biliary/fecal: ~30% as metabolites and unchanged drug.
Category C
Category C
Antipsychotic (Phenothiazine) / Antiemetic
Antiemetic